The rescuable function and mechanism of resveratrol on As2O3-induced hERG K+ channel deficiency

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 11, 2014, Pages 1079-1089

  Zhao, Xin ^a   Zhang, Kai Ping ^a   Huang, Ting ^a   Yan, Cai Chuan ^a   Liu, Li Rong ^a   Zhu, Qi Lei ^a   Guo, Feng Feng ^a   Liu, Chen ^a   Li, Bao Xin ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b State Province Key Laboratory of Biopharmaceutical Engineering   (China)

Author keywords

Arsenic trioxide (As2O3); ER stress; hERG; Hsp70 Hsp90; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CARDIOTONIC AGENT; ERG1 POTASSIUM CHANNEL; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; ORGANOARSENIC DERIVATIVE; OXIDE; POTASSIUM CHANNEL HERG; RESVERATROL; STILBENE DERIVATIVE;

ACTION POTENTIAL; ANIMAL; CARDIOTOXICITY; DEFICIENCY; DOWN REGULATION; DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; GUINEA PIG; HEART MUSCLE CELL; HEART VENTRICLE; HEK293 CELL LINE; HUMAN; METABOLISM; PATCH CLAMP TECHNIQUE; WESTERN BLOTTING;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CARDIOTOXICITY; DOWN-REGULATION; ENDOPLASMIC RETICULUM STRESS; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HEART VENTRICLES; HEK293 CELLS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MYOCYTES, CARDIAC; OXIDES; PATCH-CLAMP TECHNIQUES; STILBENES;

EID: 84937715696     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-1019-8     Document Type: Article

References (39)

1. Abriel H, Zaklyazminskaya E (2013) Cardiac channelopathies: genetic and molecular mechanisms. Gene 15:1-11
2. Baek S, Wilson L, Eling T (2002) Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23:425-432
3. Barbey J, Pezzullo J, Soignet S (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21:3609-3615
4. Baur J, Sinclair D (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506
5. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353
6. Curran M, Splawski I, Timothy K, Vincen G (1995) A molecular basis for cardiac arrhythmia: hERG mutations cause long QT syndrome. Cell 80:795-803
7. Cyranoski D (2007) Arsenic patent keeps drug for rare cancer out of reach of many. Nat Med 13:1005-1005
8. Dennis A, Wang L, Wan X, Ficker E (2007) hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35:1060-1063
9. Du X, Lu D, Daharsh E, Yao A, Dewoody R, Yao J (2006) Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells. J Pharmacol Toxicol Methods 54:164-172
10. Farkas A, Nattel S (2010) Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs 70:573-603
11. Ficker E, Obejero-Paz CA, Zhao S, Brown AM (2002) The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem 277(7):4989-4998
12. Ficker E, Dennis AT, Wang L, Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92(12):e87-e100
13. Ficker E, Kuryshev Y, Dennis A, Obejero-Paz C, Wang L, Hawryluk P, Wible B, Brown A (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44
14. Frémont L, Belguendouz L, Delpal S (1999) Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci 64:2511-2521
15. Gu DF, Li XL, Qi ZP, Shi SS, Hu MQ, Liu DM, She CB, Lv YJ, Li BX, Yang BF (2009) Blockade of hERG K∈+∈channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells. Naunyn Schmiedebergs Arch Pharmacol 380:143-151
16. Heyden M, Smits M, Vos M (2008) Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon. Br J Pharmacol 153:406-409
17. Jang M, Cai L, Udeani G, Slowing K, Thomas C, Beecher C, Fong H, Farnsworth N, Kinghorn D, Mehta R (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220
18. Kannankeril P, Roden D, Darbar D (2010) Drug-induced long QT syndrome. Pharmacol Rev 62:760-781
19. Kuryshev Y, Ficker E, Wang L, Hawryluk P, Dennis A, Wible B, Brown A, Kang J, Chen X, Sawamura K (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Therapeut 312:316-323
20. Liu Y, He X, Huang X, Ding L, Xu L, Shen Y, Zhu M, Xu B, Qi Z (2013) Resveratrol protects mouse oocytes from methylglyoxal-induced oxidative damage. PLoS One 8:e77960
21. Lu J, Kass R (2010) Recent progress in congenital long QT syndrome. Curr Opin Cardiol 25:216-221
22. Paschen W (2003) Endoplasmic reticulum: a primary target in various acute disorders and degenerative diseases of the brain. Cell Calcium 34:365-383
23. Petrovski G, Gurusamy N, Das D (2011) Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215:22-33
24. Przygoda G, Feldmann J, Cullen W (2001) The arsenic eaters of Styria: a different picture of people who were chronically exposed to arsenic. Appl Organomet Chem 15:457-462
25. + channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation 105:2830-2835
26. + channel: target and antitarget strategies in drug development. Pharmacol Res 57:181-195
27. Richard T, Pawlus A, Iglésias M, Pedrot E, Teguo W, Mérillon J, Monti J (2011) Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 1215:103-108
28. Robertson G, January C (2006) hERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handb Exp Pharmacol 171:349-355
29. Su H, Hung L, Chen J (2006) Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 290:E1339-E1346
30. Sun H, Ma L, Hu X, Zhang T (1992) Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 12:170-171
31. Vernhet L, Allain N, Vée L, Morel F, Guillouzo A, Fardel O (2003) Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Therapeut 304:145-155
32. Wan X, Dennis A, Obejero-Paz C, Overholt J, Heredia-Moya J, Kirk K, Ficker E (2011) Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome. J Biol Chem 286:2843-2852
33. Wang Y, Huang X, Zhou J, Yang X, Li D, Mao H, Sun H, Liu N, Liang J (2012) Trafficking-deficient G572R-hERG and E637K-hERG activate stress and clearance pathways in endoplasmic reticulum. PLoS One 7:e29885
34. Wu ZY, Yu DJ, Soong TW, Dawe GS, Bian J (2011) Progesterone impairs human ether-a-go-go-related gene (hERG) trafficking by disruption of intracellular cholesterol homeostasis. J Biol Chem 286:22186-22194
35. Yang B, Lin H, Xu C, Liu Y, Wang H, Han H, Wang Z (2005) Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac M3 subtype muscarinic acetylcholine receptors. Cell Physiol Biochem 16(4-6):163-174
36. Yoshida H, Okada T, Haze K, Yanagi H, Yura T, Negishi M, Mori K (2000) ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. Mol Cell Biol 20:6755-6767
37. Zhang Y, Liu Y, Wang T, Li B, Li H, Wang Z, Yang B (2006) Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms. Biochem Biophys Res Commun 340:1192-1199
38. Zhang Y, Dong Z, Jin L, Zhang K, Zhao X, Fu J, Gong Y, Sun M, Yang B, Li B (2012) Arsenic trioxide-induced hERG K+ channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression. Biochem Pharmacol 85(1):59-68
39. Zhao XY, Li G, Liu Y, Chai LM, Chen JX, Zhang Y, Lu YJ, Yang BF (2008) Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br J Pharmacol 154:105-113